



NEWS RELEASE FOR IMMEDIATE RELEASE

Contact:

Jane Grochowski, Publisher

Elsevier

+1 215-239-3712

ajmmmedia@elsevier.com

Drinking Red Wine Before Smoking Can Prevent Short Term Vascular Damage Occasional smokers can avoid some harmful effects, according to a new report in *The American Journal of Medicine*

Philadelphia, PA, November 15, 2016 – Drinking red wine is widely regarded as protective against cardiovascular disease. A new report in *The American Journal of Medicine* found that a glass or two of red wine *before* lighting up a cigarette can counteract some of the short-term negative effects of smoking on blood vessels.

Cigarette smoke causes acute endothelial damage, vascular and systemic inflammation, and cellular aging. Red wine stimulates the formation of endothelium-dependent relaxation factors such as nitric oxide, which improve endothelial function in coronary arteries possibly because of the high phenol concentration in red wine.

“However, sparse data exist on the short term potential vasoprotective effects of red wine in smoking-healthy individuals,” explained lead investigator Viktoria Schwarz, MD, of the University of Saarland, Homburg, Germany. “The aim of our study was to investigate the acute vascular effects of red wine consumption prior to ‘occasional lifestyle smoking’ in healthy individuals. We found evidence that preconsumption of red wine prevented most of the vascular injury caused by smoking.”

The study examined the effects of smoking on various biochemical processes in the blood and vessels of 20 healthy non-smokers who volunteered to smoke three cigarettes. Half of the subjects drank red wine one hour before smoking, in an amount calculated to result in 0.075% blood alcohol content. Blood and urine were collected before and after drinking and smoking and continued until 18 hours after smoking.

Smoking is known to cause microparticles to be released into the bloodstream. These particles come from endothelial cells, platelets, and monocytes and indicate that cells in the blood vessels are being damaged. Researchers found that in subjects who consumed red wine before smoking, these cellular changes did not occur.

Another biochemical process affected by smoking is telomerase activity. Telomeres can be thought of as “protective caps” on chromosomes. During aging, these caps can shorten and lose their protective ability. By measuring telomerase activity, investigators determined that the group that smoked without drinking

red wine showed a 56% decrease in telomerase activity while the drinking group showed only a 20% decrease.

Inflammation puts stress on cells due to an imbalance in reactive oxygen species production and the body's antioxidant defenses. According to Dr. Schwarz, "We observed acute proinflammatory changes, namely, leukocytosis, neutrophilia, upregulated levels of IL-6 in serum, and enhanced messenger RNA expression of IL-6 and tumor necrosis factor alpha. Our study adds to the present evidence that the proinflammatory effects in nonsmokers with 'occasional lifestyle smoking' could be prevented by red wine consumption."

Since the study was limited to young, healthy nonsmokers, it is not clear whether these findings apply to the elderly, the ill, or chronic smokers. There was no comparison to different alcoholic and non-alcoholic beverages or whether the results would apply to more than just occasional smokers and drinkers.

These findings underscore the magnitude of acute damage exerted by cigarette smoking in "occasional lifestyle smokers" and demonstrate the potential of red wine as a protective strategy to avert markers of vascular injury. Dr. Schwarz and co-investigators emphasized that they do not intend to motivate occasional smokers to drink or occasional drinkers to smoke. "Nevertheless, this study identified mechanisms suitable to explore damage and protection on the vasculature in humans, paving the way for future clinical studies."

#

NOTES FOR EDITORS

"Red Wine Prevents the Acute Negative Vascular Effects of Smoking," by Viktoria Schwarz, MD, Katrin Bachelier, MD, Stephan H. Schirmer, MD, PhD, Christian Werner, MD, Ulrich Laufs, MD, Michael Böhm, MD (DOI: <http://dx.doi.org/10.1016/j.amjmed.2016.08.025>). This article appears online in advance of *The American Journal of Medicine*, Volume 130, Issue 1 (January 2017), published by Elsevier.

Full text of this article is available to credentialed journalists upon request. Contact Jane Grochowski at +1 215-239-3712 or ajmmedia@elsevier.com to obtain copies. Journalists who would like to interview the authors should contact Viktoria Schwarz, MD, at +49 6841 1615031 or viktoria.schwarz@uks.eu.

ABOUT THE AMERICAN JOURNAL OF MEDICINE

The American Journal of Medicine (<http://www.amjmed.com>), known as the "Green Journal," is one of the oldest and most prestigious general internal medicine journals published in the United States. It has an Impact Factor of 5.61 and is ranked #13 out of 151 General and Internal Medicine titles based on number of total citations, according to the *2015 Journal Citation Reports*® published by Thomson Reuters.

AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus US medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in *The American Journal of Medicine* is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. *AJM* is published by Elsevier.

ABOUT ELSEVIER

Elsevier (www.elsevier.com) is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Elsevier Research Intelligence (www.elsevier.com/research-intelligence), and ClinicalKey (www.clinicalkey.com) — and publishes over 2,500 journals, including *The Lancet* (www.thelancet.com) and *Cell* (www.cell.com), and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group

(www.relx.com), a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com